VAXIMM
Vaximm is focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Their initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. Vaximm has shown impressive anti-tumor activity in various animal studies and will enter first human clinical trials in 2011.
VAXIMM
Social Links:
Industry:
Biotechnology Developer Platform Therapeutics
Founded:
2008-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.vaximm.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
7.8 M CHF
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Apple Mobile Web Clips Icon Google Font API WordPress SSL By Default IPv6 Apache
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Tivorsan Pharmaceuticals
Tivorsan Pharmaceuticals is a protein therapeutics company that focuses on treating neuromuscular disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
BioMedPartners
BioMedPartners investment in Venture Round - VAXIMM
BB Biotech Ventures
BB Biotech Ventures investment in Venture Round - VAXIMM
Merck
Merck investment in Venture Round - VAXIMM
Sunstone Life Science Ventures
Sunstone Life Science Ventures investment in Venture Round - VAXIMM
Official Site Inspections
http://www.vaximm.com Semrush global rank: 7.13 M Semrush visits lastest month: 883
- Host name: 217-160-0-40.elastic-ssl.ui-r.com
- IP address: 217.160.0.40
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "VAXIMM"
VAXIMM
VAXIMM is a privately held, clinical-stage biotech company developing innovative cancer treatmentsSee details»
VAXIMM company portrait | VAXIMM
VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer.See details»
VAXIMM AG - LinkedIn
Developing innovative oral T-cell immunotherapies to treat cancer patients | VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients...See details»
NEC OncoImmunity Acquires VAXIMM’s Neoantigen …
Mar 8, 2022 · NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate patients’ cytotoxic …See details»
Vaximm Company Profile 2024: Valuation, Funding & Investors
Developer of oral T-cell immunotherapy vaccines designed to offer treatment to patients suffering from cancer.See details»
Vaximm AG - Swiss Biotech
VAXIMM is developing oral T-cell immunotherapies for cancer patients. VAXIMM’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria carrying a …See details»
VAXIMM AG - News, Articles etc. - European …
Dec 4, 2014 · The Swiss-German biotech company, VAXIMM AG, has announced the enrolment of its first patient in a Phase 2a clinical trial for immunotherapy, VXM01. Phase I study evaluating safety and tolerability of …See details»
Vaximm AG Company Profile | Basel, BASEL-STADT, Switzerland ...
Find company research, competitor information, contact details & financial data for Vaximm AG of Basel, BASEL-STADT. Get the latest business insights from Dun & Bradstreet.See details»
Full article: Profile - Taylor & Francis Online
Sep 24, 2013 · VAXIMM was formed in 2008 as a joint venture of BB Biotech Ventures and Merck KGaA. VAXIMM is located in Basel, Switzerland, with an operational unit in Mannheim, Germany.See details»
VAXIMM | Biotechnology | The Pharmaletter | The Pharmaletter
VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of …See details»
Vaximm AG, Basel - business-monitor.ch
Vaximm AG is a Limited based in Basel, in the canton of Basel-City, founded in 2008. Its identification number UID is CHE-114.477.515. It is active in "other research and experimental …See details»
Vaximm AG | Insights
Oct 26, 2017 · Vaximm AG 's technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be adapted to target a wide range of cancer-related …See details»
NEC and VAXIMM Announce Collaboration to Advance …
Nov 12, 2019 · NEC and VAXIMM will co-develop personalized cancer vaccines using NEC’s cutting-edge artificial intelligence (AI) technology, which is utilized in its Neoantigen Prediction …See details»
Vaximm AG - BioCentury Company Profiles - BCIQ
Vaximm AG - BioCentury Company Profiles for the biopharma industrySee details»
VAXIMM Announces Regional Development and ... - BioPharma Dive
Sep 20, 2018 · VAXIMM will collaborate with CMS, which will have the full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs, enabling the …See details»
VAXIMM begins Phase I clinical trial of VXM01 for recurrence of ...
Jul 12, 2016 · Swiss / German biotech company VAXIMM has successfully treated the first patient in its Phase I clinical trial of VXM01 to address recurrence of glioblastoma (brain tumour). …See details»
Meeting Abstract: 2016 ASCO Annual Meeting I - ASCO Publications
May 20, 2016 · Conclusions: Oral prime boost vaccination with VXM01 was well tolerated and is suitable to induce and maintain for several months effector T cell responses against VEGFR-2 …See details»
First patient treated in Phase I VXM01 glioblastoma trial
Jul 13, 2016 · VXM01 targets the tumour-specific vasculature and certain immune-suppressive cells. It is based on a live attenuated, safe, orally available, bacterial vaccine strain, which is …See details»
VXM 01 - AdisInsight - Springer
VXM 01 is an orally administered, DNA cancer vaccine being developed by VAXIMM, under license from Merck KGaA, for the treatment of glioblastoma.See details»
Full article: A phase 1 trial extension to assess immunologic …
VXM01 is a first-in-kind orally applied tumor vaccine based on live attenuated Salmonella typhi carrying an expression plasmid encoding VEGFR2, an antigen expressed on tumor …See details»